Table 2 Treatments of patients included in the study.
| Ā | Overall Nā=ā178 | |||
|---|---|---|---|---|
Intervention ā n (%) | ||||
Topical, surgical and laser | 4 (2.2) | |||
Topical and Surgical | 4 (2.2) | |||
Topical and Laser | 27 (15.2) | |||
Only Topical | 143 (80.3) | |||
Topical Treatments ā n (%) | Baseline | 6 months | 12 months | Ā |
Ī²-blockers | 54 (30.3) | 46 (25.8) | 47 (26.4) | Ā |
Carbonic anhydrase inhibitors | 7 (3.9) | 7 (3.9) | 12 (6.7) | Ā |
Prostaglandin analogues | 96 (53.9) | 108 (60.7) | 100 (56.2) | Ā |
Parasympathomimetics | 0 (0.0) | 1 (0.6) | 1 (0.6) | Ā |
Prostaglandinā+ābeta-blocker FC | 15 (8.4) | 16 (9.0) | 26 (14.6) | Ā |
Alpha agonistā+ābeta-blocker FC | 1 (0.6) | 1 (0.6) | 1 (0.6) | Ā |
Carbonic anhydrase inhibitorā+āĪ²-blocker FC | 12 (6.7) | 18 (10.1) | 15 (8.4) | Ā |
Other | 2 (1.1) | 2 (1.1) | 2 (1.1) | Ā |
Number of active agents ā n (%) | Baseline | 6 months | 12 months | P-valuea |
0 | 0 (0.0) | 1 (0.6) | 5 (2.8) | <0.01 |
1 | 148 (83.1) | 133 (74.7) | 120 (67.9) | Ā |
2 | 23 (12.9) | 31 (17.4) | 35 (19.7) | Ā |
ā„3 | 7 (3.9) | 13 (7.3) | 18 (10.1) | Ā |
